- ISIN DE0005664809
- Land Germany
Evotec SE
Comment on media report
|
Evotec SE / Key word(s): Miscellaneous Ad hoc: Comment on media report Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) With respect to a media report, Evotec SE (“Company”) declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements. – End of the ad hoc release – Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com End of Inside Information
14-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Evotec SE |
| Manfred Eigen Campus / Essener Bogen 7 | |
| 22419 Hamburg | |
| Germany | |
| Phone: | +49 (0)40 560 81-0 |
| Fax: | +49 (0)40 560 81-222 |
| E-mail: | info@evotec.com |
| Internet: | www.evotec.com |
| ISIN: | DE0005664809 |
| WKN: | 566480 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
| EQS News ID: | 2030647 |
| End of Announcement | EQS News Service |